Thrombopoietin Receptor Agonists: Clinical Use and Evaluation of Treatment Efficacy

Idiopathic thrombocytopenic purpura (ITP), or primary immune thrombocytopenia, is an orphan disease associated with thrombocytopenia. One of the most recent and promising approaches to ITP treatment is the use of thrombopoietin receptor agonists (TPO-RAs). The scope of TPO-RA use is expanding rapidly, which stimulates the development of both innovator and generic (or biosimilar) medicines. The aim of the paper was to assess TPO-RA role in ITP treatment, methodological approaches to TPO-RA development, and feasibility of using the platelet count as a pharmacodynamic marker in bioequivalence studies of peptide TPO-RAs in healthy volunteers. Clinical development of new medicines for the treatment of thrombocytopenia includes comparative, parallel-group trials lasting about a year. The standard approach to bioequivalence studies, which is based on the results of comparative pharmacokinetic studies, can be used in marketing authorisation applications for generic non-peptide TPO agonists, while peptide TPO agonists have to comply with specific requirements for biosimilar products. The orphan status of ITP does not affect the development strategy and study design, but it limits the number of patients that could be included into the study. In the absence of valid surrogate biomarkers of efficacy, demonstration of comparable clinical efficacy of the biosimilar and reference drug is usually required in a randomised, parallel, preferably double-blind comparative study. On the other hand, clinical comparability of the biosimilar and reference drug can also be demonstrated in comparative pharmacodynamic studies, if the selected biomarker is a well-established and valid surrogate marker which correlates with patient clinical outcome. Platelet count is a key parameter in both diagnosis of diseases associated with low platelet levels and assessment of treatment efficacy. Therefore, it can be used as a pharmacodynamic marker in bioequivalence studies of biosimilar peptide TPO-RAs. It was concluded that such studies could be performed in healthy volunteers, and not in patients, whose participation in clinical trials is limited due to the orphan status of ITP.

idiopathic thrombocytopenic purpura, thrombocytopenia, thrombopoietin receptor agonists, clinical development, romiplostim

1. Williamson DR, Albert M, Heels-Ansdell D, Arnold DM, Lauzier F, Zarychanski R, et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest. 2013;144(4):1207–15. https://doi.org/10.1378/chest.13-0121

2. Smock KJ, Perkins SL. Thrombocytopenia: an update. Int J Lab Hematol. 2014;36(3):269–78. https://doi.org/10.1111/ijlh.12214

3. Gernsheimer T, James AH, Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013;121(1):38–47. https://doi.org/10.1182/blood-2012-08-448944

4. Slichter S. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev. 2004;18(3):153–67. https://doi.org/10.1016/j.tmrv.2004.03.003

5. Gauer R, Braun MM. Thrombocytopenia. Am Fam Physician. 2012;85(6):612–22. PMID: 22534274

6. MelikyanAL, Egorova EK, Pustovaya EI, Kolosheynova TI, Volodicheva EM, Kaporskaya TS, et al. Interim results of epidemiological study of idiopathic thrombocytopenic purpura in adults in the Russian Federation: intermediate results. Gematologiya i transfuziologiya = Hematology and Transfusiology. 2019;64(4):436–46 (In Russ.). https://doi.org/10.35754/0234-5730-2019-64-4-436-446

7. Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–66. https://doi.org/10.1182/bloodadvances.2019000966

8. Melikyan AL, Pustovaya EI, Egorova EK, Kalinina MV, Kolosheynova TI, et al. Differential diagnosis of thrombocytopenes. Onkogematologiya = Oncohematology. 2017;12(1):78– 87 (In Russ.). https://doi.org/10.17650/1818-8346-2017-12-1-78-87

9. Rakhmani AF, Mikhaylova EA, Dubinkin IV, Kalmykova OS, Galuzyak VS, Troitskaya VV, et al. Refractoriness to donor platelets transfusion in patients with aplastic anemia and hemoblastosis. Onkogematologiya = Oncohematology. 2018;13(2):62– 72 (In Russ.). https://doi.org/10.17650/1818-8346-2018-13-2-62-72

10. Debili N, Wendling F, Cosman D, Titeux M, Florindo C, DusanterFourt I, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood. 1995;85(2):391– 401. PMID: 7529061

11. Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999;106(2):345–56. https://doi.org/10.1046/j.1365-2141.1999.01571.x

12. Choi ES, Nichol JL, Hokom MM, Hornkohl AC, Hunt P. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood. 1995;85(2):402–13. PMID: 7529062

13. Zauli G, Vitale M, Falcieri E, Gibellini D, Bassini A, Celeghini C, et al. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood. 1997;90(6):2234–43. PMID: 9310474

14. Kuter DJ. Milestones in understanding platelet production: a historical overview. Br J Haematol. 2014;165(2):248–58. https://doi.org/10.1111/bjh.12781

15. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science. 1997;276(5319):1696–9. https://doi.org/10.1126/science.276.5319.1696

16. Wang B, Nichol J, Sullivan J. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76(6):628–38. https://doi.org/10.1016/j.clpt.2004.08.010

17. Shirasugi Y, Ando K, Hashino S, Nagasawa T, Kurata Y, Kishimoto Y, et al. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Int J Hematol. 2009;90(2):157–65. https://doi.org/10.1007/s12185-009-0361-y

18. Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee J-W, Andriulli A, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367(8):716–24. https://doi.org/10.1056/NEJMoa1110709

19. Severinsen MT, Engebjerg MC, Farkas DK, Jensen AØ, Nørgaard M, Zhao S, et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2011;152(3):360–2. https://doi.org/10.1111/j.1365-2141.2010.08418.x

20. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395–403. https://doi.org/10.1016/S0140-6736(08)60203-2

21. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190– 207. https://doi.org/10.1182/blood-2010-08-302984

22. Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527–36. https://doi.org/10.1182/blood-2017-04-748707

23. Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013;368(19):1771–80. https://doi.org/10.1056/NEJMoa1212772

24. Stanworth SJ, Dyer C, Choo L, Bakrania L, Copplestone A, Llewelyn C, et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfus Med Rev. 2010;24(3):163–71. https://doi.org/10.1016/j.tmrv.2009.11.002

25. Wood EM, Hudson C, Estcourt L, Johnson R, Stanworth SJ. Risk factors for bleeding: a modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood. 2014;124(21):1551. https://doi.org/10.1182/blood.V124.21.1551.1551

26. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161–71. https://doi.org/10.1182/blood-2008-04-150078

27. Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D, et al. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017;102(8):1342–51. https://doi.org/10.3324/haematol.2016.161968